Evidence map›Paper›PMID 20954430›Full record

ReviewDialogues in clinical neuroscience2010

Pharmacologic treatment of schizophrenia.

John M Kane, Christoph U Correll

Open access · diamondAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in Dialogues in clinical neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 8 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 8 syntheses or guidelines pooled it, 169 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Exercise to treat psychopathology and other clinical outcomes in schizophrenia: A systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2023
    Pooled it
  4. Pooled it
  5. Natural Medicines for Psychotic Disorders: A Systematic Review.The Journal of nervous and mental disease · 2018
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Potential Roles for the GluN2D NMDA Receptor Subunit in Schizophrenia.International journal of molecular sciences · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

John M KaneZucker Hillside Hospital, 75-59 263rd Street, Glen Oaks, NY 11004, USA. psychiatry@lij.edu
Christoph U Correll
Albert Einstein College of Medicine · USNorthwell Health · US

Funding

Trials Operation UnitP30MH074543 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI KANE, JOHN M · 2005 to 2009
$8.1M
Trials Operation Unit (OPERATIONS CORE)P30MH090590 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI CORRELL, CHRISTOPH U · 2010 to 2014
$7.9M
NIMH NIH HHS MH074543-01NIMH NIH HHS P30 MH074543NIMH NIH HHS P30 MH090590
6 · The paper itself

Abstract

Despite pharmacologic advances, the treatment of schizophrenia remains a challenge, and suboptimal outcomes are still all too frequent. Although treatment goals of response, remission, and recovery have been defined more uniformly, a good "effectiveness" measure mapping onto functional outcomes is still lacking. Moreover, the field has to advance in transferring measurement-based approaches from research to clinical practice. There is an ongoing debate whether, and which, first- or second-generation antipsychotics should be used. However an individualized treatment approach needs to consider current symptoms, comorbid conditions, past therapeutic response, and adverse effects, as well as patient choice and expectations. Moreover acute and long-term goals and effects of medication treatment need to be balanced. While the acute response to appropriately dosed first-generation antipsychotics may not differ much from second-generation antipsychotics, advantages of lower rates of extrapyramidal side effects, tardive dyskinesia, and, possibly, relapse may favor second-generation antipsychotics. However when considering individual adverse effect profiles, the differentiation into first- and second-generation antipsychotics as unified classes can not be upheld, and a more differentiated view and treatment selection is required. To date, clozapine is the only evidence-based treatment for refractory patients, and the role of antipsychotic polypharmacy and other augmentation strategies remains unclear, at best. To improve the treatment outcomes in schizophrenia, research efforts are needed that elucidate biomarkers of the illness and of treatment response (both therapeutic and adverse effects). Moreover, new treatment options are needed that affect nondopaminergic targets with relevance for symptom reduction, relapse prevention, enhanced efficacy for nonresponders, and reduced key adverse effects.

Indexed as

AnimalsAntipsychotic AgentsHumansSchizophreniaTime FactorsTreatment OutcomeAntipsychotic Agents

Identifiers

PMID20954430
PMCPMC3085113
OpenAlexW1567719012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.